Selinexor with standard chemo for high-risk lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 trial studies selinexor added to standard R-CHOP chemotherapy in people with a high-risk type of diffuse large B-cell lymphoma (DLBCL) that is “germinal center B-cell” (GC). It aims to improve disease control in people who need stronger treatment at the start.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 75, and you can sign informed consent
- Your lymphoma biopsy confirms DLBCL, germinal-center B-cell subtype (per the Hans test)
- You have not had chemo or radiation for this DLBCL before (except up to 5 days of steroids for symptom relief)
- Your lymphoma scans show measurable disease (PET/CT positive with specific size rules)
- Your overall condition is good enough for chemo (ECOG performance status 0–2)
- Your blood counts and organ function (kidneys, liver, bone marrow) meet lab minimums
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding selinexor to the standard R-CHOP chemotherapy for people with a specific type of diffuse large B-cell lymphoma (DLBCL) that has a TP53 mutation. The goal is to see if this combination works better as the first treatment.
This early-phase study tests whether selinexor combined with VRd (bortezomib, lenalidomide, and dexamethasone) can improve outcomes for people with high-risk, newly diagnosed multiple myeloma. You may be a candidate if you have certain lab/genetic signs of “high-risk” disease and haven’t had prior myeloma treatment.
This trial tests a new drug, selinexor, combined with standard ICE chemotherapy for patients whose B-cell non-Hodgkin lymphoma has spread to the brain or spinal cord. It aims to see if adding selinexor improves treatment results.
This trial tests a new combination: selinexor (a pill that targets cancer cells) plus a standard chemotherapy regimen (R-GDP) for people with relapsed or refractory DLBCL that has a specific genetic change in the TP53 gene. The goal is to see if this combination can help when other treatments have stopped working.
This trial tests selinexor given together with methotrexate and rituximab to treat lymphoma that has returned or not responded in the brain. It may help by attacking cancer cells in the central nervous system (brain/spinal fluid) after prior treatment.
This trial tests a combination of three drugs (selinexor, pegaspargase, and dexamethasone) for people with newly diagnosed NK/T-cell lymphoma. It aims to see if this treatment can shrink tumors and be safe.
Hear when a new DLBCL Germinal Center B-Cell Type trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.